|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A BRAF V600E mutation was identified in 15% of PD-L1-positive malignancies.
|
31821747 |
2020 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A set of 668 stage II and III CC samples from the PETACC-3 (Pan-European Trails in Alimentary Tract Cancers) clinical trial were used to assess differential gene expression between c.1799T>A (p.V600E) BRAF mutant and non-BRAF, non-KRAS mutant cancers (double wild type) and to construct a gene expression-based classifier for detecting BRAF mutant samples with high sensitivity.
|
22393095 |
2012 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas.
|
21107323 |
2010 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although the presence of the BRAF V600E mutation is indicative of a sporadic cancer, up to 30% to 50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a BRAF mutation.
|
27438990 |
2016 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 75% of the cases were cytologically diagnosed as being positive for malignancy and these cases were associated with both the classic and tall cell variants of PTC at the time of resection, a greater likelihood of extrathyroidal extension, and the V600E type of BRAF mutation.
|
22887810 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
As a single agent, vemurafenib is relatively ineffective in other V600E-positive malignancies</span>.
|
30036146 |
2018 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Besides confirming the constant presence of BRAF-V600E in all patients with hairy cell leukemia, we observed ubiquitous phospho-ERK expression in this malignancy.
|
23349307 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) mutation was found in about one in two nodules with thyroid FNA read as SFM, its PPV to detect cancers was excellent, and its NPV was very poor.
|
31811566 |
2020 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
|
30219154 |
2018 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E Mutation in Multiple Primary Malignancies: A Hairy Affair.
|
30680261 |
2018 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutations are also present in benign melanocytic naevi, highlighting the importance of additional genetic alterations in the genesis of malignant tumours.
|
21430779 |
2011 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E)-mutated DNA was quantified in plasma samples and in cancer sections by quantitative real-time polymerase chain reaction (qPCR).
|
24858900 |
2014 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Braf(V600E)-driven tumors require autophagy and likely autophagy-provided substrates to maintain mitochondrial metabolism and to promote tumor growth, suggesting that autophagy ablation may improve cancer therapy.
|
24860158 |
2014 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF-V600E mutations are found in a broad spectrum of cancer types and can be successfully targeted by specific therapeutic compounds.
|
23343956 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cytomorphologic features can help select nodules for the BRAF(V600E) mutation test among nodules read as "suspicious for malignancy" on cytology.
|
26187369 |
2015 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of BRAF(V600E) mutation had limited value in diagnoses of malignancy in follicular neoplasms but can ascertain malignancy in subset of suspicious for malignancy FNABs.
|
21948220 |
2011 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E mutation is therefore a useful adjunct in the differential diagnosis of HCL and HCL variant and highlights the value of a multifaceted approach to the diagnosis of this malignancy.
|
22313586 |
2012 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
|
25353071 |
2015 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Elucidating the spectrum of non-p. V600E BRAF mutations in different malignancies is a first step toward understanding their clinical significance.
|
26386083 |
2015 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: correlation with late disease onset.
|
23263826 |
2013 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
For the 37 cases cytologists favored to be cPTC, 31 (84%) had a molecular result that supported malignancy (28 BRAF V600E mutations, 2 NTRK1 fusions, 1 AGK-BRAF fusion).
|
29396809 |
2018 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.
|
12068308 |
2002 |
|
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene.
|
16266992 |
2005 |